1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Advanced Solid Tumors Harboring the KRAS G12C Mutation: new trials by email Literature Review of Advanced Solid Tumors Harboring the KRAS G12C Mutation trials Research Report on Advanced Solid Tumors Harboring the KRAS G12C Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Rectal Diseases (1) · Respiratory Tract Diseases (1)
Cetuximab (1) · JDQ443 (1) · tislelizumab (1) · trametinib (1)
Belgium (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Italy (1) · Japan (1) · Malaysia (1) · South Korea (1) · Spain (1)
2025 (1)